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2009-2010 Influenza Season Week 11 ending March 20, 2010
All data are preliminary and may change as more reports are received.
Synopsis:
During week 11 (March 14-20, 2010), influenza activity remained at approximately the same
levels as last week in the U.S.
139 (4.6%) specimens tested by U.S. World Health Organization (WHO) and National
Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories
and reported to CDC/Influenza Division were positive for influenza.
Approximately 99% of all subtyped influenza A viruses reported to CDC were 2009
influenza A (H1N1) viruses.
The proportion of deaths attributed to pneumonia and influenza (P&I) was below the
epidemic threshold.
One influenza-associated pediatric death was reported and was associated with an
influenza A virus for which the subtype was undetermined.
The proportion of outpatient visits for influenza-like illness (ILI) was 1.8%, which is
below the national baseline of 2.3%. Three of 10 regions (Regions 4, 7, and 9) reported
ILI at or above region-specific baseline levels.
No states reported widespread influenza activity. Three states reported regional
influenza activity. Puerto Rico and eight states reported local influenza activity. The
District of Columbia, Guam and 31 states reported sporadic influenza activity. Eight
states reported no influenza activity, and the U.S. Virgin Islands did not report.
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Nation Normal 4.6 % 3 of 54 34 63 66,050 289 22,199 284 268
Region 1 Normal 1.5 % 0 of 6 4 4 3,402 14 502 11 6
Region 2 Normal 1.7 % 0 of 4 8 5 1,794 0 2,395 12 18
Region 3 Normal 1.9 % 0 of 6 3 11 10,686 48 1,452 18 14
Region 4 Elevated 15.2 % 3 of 8 0 7 9,527 95 4,598 85 51
Region 5 Normal 3.7 % 0 of 6 8 25 9,474 47 1,576 19 36
Region 6 Normal 6.6 % 0 of 5 2 3 5,069 19 5,342 54 71
Region 7 Elevated 7.2 % 0 of 4 3 1 3,247 3 843 9 8
Region 8 Normal 1.2 % 0 of 6 4 2 9,845 0 3,931 56 16
Region 9 Elevated 0.3 % 0 of 5 0 4 8,326 49 1,214 17 38
Region 10 Normal 1.1 % 0 of 4 2 1 4,680 14 346 3 10
*Influenza season officially begins each year at week 40. This season data from week 35 will
be included to show the trend of influenza activity before the official start of the 2009-10
influenza season.
**HHS regions (Region 1 CT, ME, MA, NH, RI, VT; Region 2: NJ, NY, Puerto Rico, US Virgin
Islands; Region 3: DE, DC, MD, PA, VA, WV; Region 4: AL, FL, GA, KY, MS, NC, SC, TN;
Region 5: IL, IN, MI, MN, OH, WI; Region 6: AR, LA, NM, OK, TX; Region 7: IA, KS, MO, NE;
Region 8: CO, MT, ND, SD, UT, WY; Region 9: AZ, CA, Guam, HI, NV; and Region 10: AK, ID,
OR, WA).
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline
‡ National data are for current week; regional data are for the most recent three weeks
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands
¥ Subtyping results for the majority of specimens in this category were inconclusive because
of low virus titers.
U.S. Virologic Surveillance:
WHO and NREVSS collaborating laboratories located in all 50 states and Washington, D.C.
report to CDC the number of respiratory specimens tested for influenza and the number
positive by influenza type and subtype. The results of tests performed during the current week
are summarized in the table below.
Week 11
No. of specimens tested 3,050
No. of positive specimens (%) 139 (4.6%)
Positive specimens by type/subtype
  Influenza A 137 (98.6%)
             A (2009 H1N1) 80 (58.4%) 
             A (subtyping not performed) 56 (40.9%) 
             A (unable to subtype) 0 (0.0%) 
             A (H3) 1 (0.7%) 
             A (H1) 0 (0.0%) 
  Influenza B 2 (1.4%)
During week 11, two influenza B viruses and one influenza A (H3N2) virus were reported,
although approximately 99% of all subtyped influenza A viruses reported to CDC this week
were 2009 influenza A (H1N1) viruses.
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Pneumonia and Influenza Hospitalization and Death
Tracking:
The Aggregate Hospitalization and Death Reporting Activity (AHDRA) system was
implemented on August 30, 2009, and replaces the weekly report of laboratory confirmed 2009
H1N1-related hospitalizations and deaths that began in April 2009. Jurisdictions report to CDC
the number of hospitalizations and deaths resulting from all types or subtypes of influenza, not
just those associated with 2009 H1N1. Counts were reset to zero on August 30, 2009. From
August 30, 2009 – March 20, 2010, 41,551 laboratory-confirmed influenza-associated
hospitalizations and 2,077 laboratory-confirmed influenza-associated deaths were reported to
CDC.
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Antigenic Characterization:
CDC has antigenically characterized two seasonal influenza A (H1N1), 12 influenza A (H3N2),
23 influenza B, and 1,608 2009 influenza A (H1N1) viruses collected since September 1, 2009.
Both seasonal influenza A (H1N1) viruses tested were related to the influenza A (H1N1)
component of the 2009-10 Northern Hemisphere influenza vaccine (A/Brisbane/59/2007).
The 12 influenza A (H3N2) viruses tested showed reduced titers with antisera produced against
A/Brisbane/10/2007, the 2009-2010 Northern Hemisphere influenza A (H3N2) vaccine
component, and were antigenically related to A/Perth/16/2009, the WHO recommended
influenza A (H3N2) component of the 2010 Southern Hemisphere and 2010-11 Northern
Hemisphere vaccine formulations.
Influenza B viruses currently circulating globally can be divided into two distinct lineages
represented by the B/Yamagata/16/88 and B/Victoria/02/87 viruses. The influenza B
component of the 2009-10 and 2010-11 Northern Hemisphere vaccines belongs to the
B/Victoria lineage. The 23 influenza B viruses tested belong to the B/Victoria lineage and are
related to the influenza vaccine component for the 2009-10 and 2010-11 Northern Hemisphere
influenza B vaccine strain (B/Brisbane/60/2008).
One thousand six hundred three (99.7%) of 1,608 2009 influenza A (H1N1) viruses tested are
related to the A/California/07/2009 (H1N1) reference virus selected by WHO as the 2009 H1N1
vaccine virus, and as a component in the 2010-11 Northern Hemisphere vaccine. Five viruses
(0.3%) tested showed reduced titers with antiserum produced against A/California/07/2009.
Annual influenza vaccination is expected to provide the best protection against those virus
strains that are related to the vaccine strains, but limited to no protection may be expected
when the vaccine and circulating virus strains are so different as to be from different lineages.
Antigenic characterization of 2009 influenza A (H1N1) viruses indicates that these viruses are
only distantly related antigenically and genetically to seasonal influenza A (H1N1) viruses,
suggesting that little to no protection would be expected from vaccination with seasonal
influenza vaccine.
Composition of the 2010-11 Influenza Vaccine:
WHO has recommended vaccine strains for the 2010-11 Northern Hemisphere trivalent
influenza vaccine, and FDA has made the same recommendations for the U.S. influenza
vaccine. Both agencies recommend that the vaccine contain A/California/7/2009-like (2009
H1N1), A/Perth/16/2009-like (H3N2), and B/Brisbane/60/2008-like (B/Victoria lineage) viruses.
A seasonal influenza A (H1N1) component is not included in the 2010-11 formulation and the A
(H3N2) component has been changed from the 2009-10 Northern Hemisphere vaccine
formulation. This recommendation was based on surveillance data related to epidemiology and
antigenic characteristics, serological responses to 2009-10 trivalent seasonal and 2009 H1N1
monovalent vaccines, and the availability of candidate strains and reagents.
Antiviral Resistance:
Since September 1, 2009, one seasonal influenza A (H1N1), 13 influenza A (H3N2), 17
influenza B, and 1,588 2009 influenza A (H1N1) virus isolates have been tested for resistance
to the neuraminidase inhibitors (oseltamivir and zanamivir), and 2,573 2009 influenza A (H1N1)
original clinical samples were tested for a single known mutation in the virus that confers
oseltamivir resistance. In addition, one seasonal influenza A (H1N1), 13 influenza A (H3N2), and
1,608 2009 influenza A (H1N1) virus isolates have been tested for resistance to the
adamantanes (amantadine and rimantadine). The results of antiviral resistance testing
performed on these viruses are summarized in the table below. Additional laboratories perform
antiviral testing and report their results to CDC, and positive results from that testing are
included in the footnote.
Antiviral Resistance Testing Results on Samples Collected Since September 1, 2009.
Number (%)
Samples tested
(n)
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(n)
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Samples
tested
(n)
Resistant
Viruses,
Number (%)
Oseltamivir Zanamivir Adamantanes
Seasonal
Influenza A
(H1N1)
1 1 (100.0) 0 0 (0) 1 0 (0)
Influenza A
(H3N2) 13 0 (0) 0 0 (0) 13 13 (100.0)
Influenza B 17 0 (0) 0 0 (0) N/A* N/A*
2009 Influenza
A (H1N1) 4,161 50†‡ (1.2) 1,588 0 (0) 1,608 1,604 (99.8)
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses.
†Two screening tools were used to determine oseltamivir resistance: sequence analysis of viral
genes or a neuraminidase inhibition assay.
‡Additional laboratories perform antiviral resistance testing and report their results to CDC.
Three additional oseltamivir resistant 2009 influenza A (H1N1) virus has been identified by
these laboratories since September 1, 2009, bringing the total number to 53.
Approximately 99% of all subtyped influenza A viruses reported during week 11 were 2009
influenza A (H1N1) viruses, and nearly all of 2009 H1N1 viruses tested since April 2009 have
been resistant to the adamantanes (amantadine and rimantadine).
Antiviral treatment with oseltamivir or zanamivir is recommended for all patients with confirmed
or suspected influenza virus infection who are hospitalized or who are at higher risk for
influenza complications. Additional information on antiviral recommendations for treatment and
chemoprophylaxis of influenza virus infection is available at
http://www.cdc.gov/h1n1flu/recommendations.htm.
2009 influenza A (H1N1) viruses were tested for oseltamivir resistance by a neuraminidase
inhibition assay and/or detection of genetic sequence mutation, depending on the type of
specimen tested. Original clinical samples were examined for a single known mutation in the
virus that confers oseltamivir resistance in currently circulating seasonal influenza A (H1N1)
viruses, while influenza virus isolates were tested using a neuraminidase inhibition assay that
determines the presence or absence of neuraminidase inhibitor resistance, followed by
neuraminidase gene sequence analysis of resistant viruses.
The majority of 2009 influenza A (H1N1) viruses are susceptible to the neuraminidase inhibitor
antiviral medication oseltamivir; however, rare sporadic cases of oseltamivir resistant 2009
influenza A (H1N1) viruses have been detected worldwide. A total of 62 cases of oseltamivir
resistant 2009 influenza A (H1N1) viruses have been identified in the United States since April
2009. This total includes one newly identified case since last week. Fifty-three of these
specimens were collected after September 1, 2009. The proportion of oseltamivir-resistant
2009 H1N1 viruses does not represent the prevalence of oseltamivir-resistant 2009 H1N1 in
the United States Most cases were tested because drug resistance was suspected. All tested
viruses retain their sensitivity to the neuraminidase inhibitor zanamivir. Of the 62 total cases
identified since April 2009, 50 patients had documented exposure to oseltamivir through either
treatment or chemoprophylaxis, eight patients are under investigation to determine exposure
to oseltamivir, three patients had no documented oseltamivir exposure, and in one patient,
exposure cannot be determined. Occasional development of oseltamivir resistance during
treatment or prophylaxis is not unexpected. Enhanced surveillance, an increased availability of
testing performed at CDC, and an increasing number of public health and other clinical
laboratories performing antiviral resistance testing increase the number of cases of oseltamivir
resistant 2009 influenza A (H1N1) viruses detected. All cases are investigated to assess the
spread of resistant strains in the community.
To prevent the spread of antiviral resistant virus strains, CDC reminds clinicians and the public
of the need to continue hand and cough hygiene measures for the duration of any symptoms
of influenza, even while taking antiviral medications
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5832a3.htm).
Pneumonia and Influenza (P&I) Mortality Surveillance
During week 11, 7.7% of all deaths reported through the 122-Cities Mortality Reporting
System were due to P&I. This percentage was below the epidemic threshold of 7.8% for week
11.
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Influenza-Associated Pediatric Mortality
One influenza-associated pediatric death was reported to CDC during week 11 (Mississippi)
and was associated with an influenza A virus for which the subtype was undetermined. This
death occurred during week 9 (the week ending March 6, 2010).
Since August 30, 2009, CDC has received 268 reports of influenza-associated pediatric deaths
that occurred during the current influenza season (48 deaths in children less than 2 years old,
30 deaths in children 2-4 years old, 100 deaths in children 5-11 years old, and 90 deaths in
children 12-17 years old). Two hundred eighteen (81%) of the 268 deaths were due to 2009
influenza A (H1N1) virus infections, 49 were associated with an influenza A virus for which the
subtype is undetermined, and one was associated with an influenza B virus infection. A total of
278 deaths in children associated with 2009 influenza A (H1N1) virus infection have been
reported to CDC.
Among the 268 deaths in children, 143 children had specimens collected for bacterial culture
from normally sterile sites and 49 (34.3%) of the 143 were positive; Streptococcus pneumoniae
was identified in 11 (22.4%) of the 49 children, and Staphylococcus aureus was identified in 14
(28.6%) of the 49 children. Four S. aureus isolates were sensitive to methicillin, nine were
methicillin resistant, and one did not have sensitivity testing performed. Thirty-two (65.3%) of
the 49 children with bacterial coinfections were five years of age or older, and 17 (34.7%) of
the 49 children were 12 years of age or older.
Laboratory-Confirmed Influenza-Associated Pediatric Deaths by Date and Type/Subtype
of Influenza.
Date 2009 H1N1Influenza
Influenza A-
Subtype
Unknown
Seasonal
Influenza Total
Number of Deaths REPORTED for Current Week
– Week 11 (Week ending March 20, 2010) 0 1 0 1
Number of Deaths OCCURRED since August
30, 2009 218 49 1 268
Number of Deaths OCCURRED since April
26, 2009 278 52 2 332
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Influenza-Associated Hospitalizations
Laboratory-confirmed influenza-associated hospitalizations are monitored using a population-
based surveillance network that includes the 10 Emerging Infections Program (EIP) sites (CA,
CO, CT, GA, MD, MN, NM, NY, OR and TN) and 6 new sites (IA, ID, MI, ND, OK and SD).
During September 1, 2009 – March 20, 2010, the following preliminary laboratory-confirmed
overall influenza associated hospitalization rates were reported by EIP and the new sites (rates
include influenza A, influenza B, and 2009 influenza A (H1N1)):
Rates [EIP (new sites)] for children aged 0-4 years and 5-17 years were 6.5 (10.4) and 2.5 (3.6)
per 10,000, respectively. Rates [EIP (new sites)] for adults aged 18-49 years, 50-64 years, and
≥ 65 years were 2.4 (1.7), 3.1 (2.0) and 2.7 (1.8) per 10,000, respectively.
*The 2008-09 EIP rate ended as of April 14, 2009 due to the onset of the 2009 H1N1 season.
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Outpatient Illness Surveillance:
Nationwide during week 11, 1.8% of patient visits reported through the U.S. Outpatient
Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This
percentage is below the national baseline of 2.3%
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.5% to 3.5% during
week 10. Three of the 10 regions (Region 4, 7, and 9) reported ILI at or above region-specific
baseline levels. (Note: Use of the national baseline for regional ILI data or regional baselines for
state-level data is not appropriate)
Geographic Spread of Influenza as Assessed by State and
Territorial Epidemiologists:
The influenza activity reported by state and territorial epidemiologists indicates geographic
spread of both seasonal influenza and 2009 influenza A (H1N1) viruses and does not measure
the severity of influenza activity.
During week 11, the following influenza activity was reported:
No states reported widespread influenza activity.
Regional influenza activity was reported by three states (Alabama, Georgia, and
South Carolina).
Local influenza activity was reported by Puerto Rico and eight states (Arkansas,
Hawaii, Louisiana, Mississippi, New Mexico, North Carolina, Tennessee, and
Virginia).
Sporadic influenza activity was reported by the District of Columbia, Guam, and
31 states (Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida,
Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Michigan, Minnesota,
Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma,
Pennsylvania, South Dakota, Texas, Utah, Vermont, Washington, West Virginia,
and Wisconsin).
Eight states (Idaho, Massachusetts, Nebraska, New Hampshire, North Dakota,
Oregon, Rhode Island, and Wyoming) reported no influenza activity.
The U.S. Virgin Islands did not report.
